The MGH Center for Women’s Mental Health has a special registry for women who take atypical antipsychotic medications during pregnancy. This is a very important registry given the lack of information that exists about certain types of medications and their potential impact on the health of babies.

Atypical antipsychotics are often used to treat mania or bipolar depression. They include such medications as Abilify, Zyprexa, Seroquel and Risperdal.

The MGH National Pregnancy Registry for Atypical Antipsychotics is the first hospital-based pregnancy registry for atypical antipsychotics in North America. The Registry is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy.

You are eligible to participate in the study if you are a pregnant woman aged 18-45 who is currently treated with one or more of the following atypical antipsychotics:

• Abilify (aripiprazole)
• Clozaril (clozapine)
• Geodon (ziprasidone)
• Invega (paliperidone)
• Risperdal (risperidone)
• Seroquel (quetiapine)
• Zyprexa (olanzapine)
• Saphris (asenapine)
• Latuda (lurasidone)

Participation involves three brief phone interviews over a period of approximately eight months.  To participate, call toll-free 1-866-961-2388 or email registry@womensmentalhealth.org.

If you are a healthcare provider interested in referring someone to the Registry, please have your patient call or email them, because this is a patient-initiated registry. 

Please share this information with anyone who might benefit.